about
Carbohydrate-mimetic peptides for pan anti-tumor responsesThe Patterns of Coevolution in Clade B HIV Envelope's N-Glycosylation SitesAntigen binding of human IgG Fabs mediate ERK-associated proliferation of human breast cancer cells.Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?Impact of Antigen Density on the Binding Mechanism of IgG AntibodiesBridging innate and adaptive antitumor immunity targeting glycans.Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity.Defining the recognition elements of Lewis Y-reactive antibodies.Tumor-Associated Glycans and Immune SurveillanceAntibody repertoire profiling with mimotope arrays.The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites.Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes.Carbohydrate targets in HIV vaccine research: lessons from failures.Carbohydrate mimetic peptides augment carbohydrate-reactive immune responses in the absence of immune pathology.The promise of the anti-idiotype concept.The Potential Role of Solvation in Antibody Recognition of the Lewis Y Antigen.In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens.The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.Enhancement of the Affinity of Glucocorticoid Receptors as a Mechanism Underlying the Steroid-sparing Effect of Intravenous Immunoglobulin: Figure 1Heterogeneous antigen recognition behavior of induced polyspecific antibodiesThe Promise of Anti-idiotype RevisitedPreclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanomaImmune surveillance as a rationale for immunotherapy?Serum IgM, IgG and IgA block by F(ab')-dependent mechanism the binding of natural IgG autoantibodies from therapeutic immunoglobulin preparations to self-antigensThe autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods usedAntibody polyspecificity: what does it matter?The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells responseThinking CancerDiagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries
P50
Q27023624-89CB56FB-1AD6-4FB0-94AA-A7859BB885F1Q30376065-71FEC845-CE6B-404E-9170-A155D1DE4959Q30777967-909F9285-3528-496A-8059-7176FD09604BQ33414109-172849E9-3DE9-419D-89F6-CA95B7113E6FQ33812798-DBBEAAF4-BEEC-4312-BAEF-2090B6DD843FQ33960021-F47F732E-8045-4280-89E7-DAEBF914340EQ35104042-3141A4BF-1220-4576-9E89-3C636EE28A29Q35223746-154574C5-9D3F-455D-B391-6C32B9B7953EQ35890610-493170E4-3CCB-48D7-B703-FE7076081282Q36215753-794AA66A-6AC8-45B9-8904-6C7C8AF808DDQ36894391-C8087A7D-42EA-410C-8132-BA1E03A7F4F6Q37170492-320C73F5-32FB-477F-BE63-7C8BC9EB031AQ37773298-7ABF7DFC-E803-4C54-8D7B-0C08B86B4179Q41825879-695422AE-EA32-4AE2-8F2F-CD1AA356D9C6Q42419120-6540EFD4-65FF-41CE-9805-FA41B3C68A99Q43196915-4C9D2B94-B67E-491C-BD95-3FD91392274BQ45857166-6AD667C4-BCBA-4249-9865-3EC0E6583F47Q46546681-AD764EC7-7AD1-4853-9D2D-0864EC842942Q47128233-27FAAA7A-65C2-42DE-918E-5997578A6995Q47135344-48DCB1A5-9DBC-4A47-8128-CA765363F0FBQ58861243-7EEA2B56-CDAA-4211-851F-21C19C9006AFQ58861256-27F9081D-1BA0-4BDF-B807-452FEECDEB84Q64118739-99A39337-5BFA-4403-9D10-CBA11A7B6C27Q79781496-D213E883-143C-41C9-832D-215CEE1EADD3Q80694404-743B13DB-C675-44EE-B084-A46A99142B1FQ81283572-46EB5224-458F-4CD9-A58C-06EA193426C5Q81688765-8121B358-9B70-4E5C-A8AB-F7E790B0AEEBQ84823631-D3E9B0AF-0EBC-4EA4-AFE0-2660B6253FCCQ85586359-5A5A4654-F0BF-44FB-9BC9-F11CFB44E22DQ89233298-51321C7B-7FBD-4E80-9651-3A8A0C4CDBE3Q92072210-D3DBC73F-4490-4A51-A066-DEA1954FAD3A
P50
description
researcher ORCID ID = 0000-0002-6033-3566
@en
wetenschapper
@nl
name
Anastas Pashov
@ast
Anastas Pashov
@en
Anastas Pashov
@es
Anastas Pashov
@nl
type
label
Anastas Pashov
@ast
Anastas Pashov
@en
Anastas Pashov
@es
Anastas Pashov
@nl
prefLabel
Anastas Pashov
@ast
Anastas Pashov
@en
Anastas Pashov
@es
Anastas Pashov
@nl
P108
P106
P108
P31
P496
0000-0002-6033-3566